Corrections or additions?
This article by Barbara Fox was prepared for the September 18, 2002 edition of U.S. 1 Newspaper. All rights reserved.
Technology Who’s Who
B>Geoffrey M. Nichol has left Novartis Pharmaceuticals
Corporation to be senior vice president of product development at
Medarex Inc. on Route 206. At SmithKline Beecham Pharmaceuticals (now
GlaxoSmithKline) he was involved in the development and commercialization
of the antibiotic product, Augmentin.
At Novartis he had been head of global project management, vice president
and head of U.S. medical affairs, and vice president and head of respiratory,
bone, and HRT clinical research.
Nichol has an MD from University Medical School in New Zealand, and
an MBA from Warwick University in the United Kingdom. With the UltiMAb
Human Antibody Development System, Medarex develops monoclonal antibody-based
therapeutics for cancer and other diseases,
Leonard L. Kaplan, who has a Nassau Street-based pharmaceuticalconsulting service, has received approval and allowance of his claimfor a patent on a transdermal method of diagnosing and treating AIDS,hepatitis, cancer, and other infection diseases. He and his associate,William R. Levis, attending dermatologist at New York MedicalCenter, are ready to begin clinical studies at the Bellevue MedicalCenter.”Our product is a generalized immune system stimulant that willbe of value for the diagnosis and treatment of AIDS, hepatitis, EpsteinBarr syndrome, and other viral infections — any situation wherethe immune system is compromised,” says Kaplan. “It will boostthe immune system, the T-lymphocyte (CD4, CD8) and natural killercells, through the dendritic antigen presenting cells — in orderto combat infection without use of outside agents such as interferons.”His company, Pharmaceutical Quality Associates at 20 Nassau Street(609-683-9484), offers consulting services and product developmentfor innovative oral and topical drug delivery systems. A native NewYorker, Kaplan earned his pharmacy degree from Ohio State in 1952and has a PhD from New York University. After working for RichardsonVicks he joined Johnson & Johnson, where he was vice president ofresearch in the Advanced Care Products division. He later worked withSterling Winthrop Research in Rensselaer, New York.AIDS research is shifting dramatically from high activity antiretroviraltherapy to immune system stimulation of immunocompromised patients,says Kaplan. His patented transdermal compositions contain a safeand effective delayed sensitizer drug that induces stimulation ofcell-mediated immune responses in responsive patients. AIDS will bethe first FDA-approved use for this treatment, followed by hepatitis,which often accompanies HIV infections.”I just had an inquiry from Korea regarding Hepatitis B, an epidemicsexual transmitted disease,” says Kaplan. “Dr. Levis and Iare funding it ourselves through my company here. We are very excitedabout it.”— Barbara FoxPrevious StoryNext StoryCorrections or additions?This page is published by PrincetonInfo.com— the web site for U.S. 1 Newspaper in Princeton, New Jersey.
